391 related articles for article (PubMed ID: 35287535)
21. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease.
Kim J; Choi MS; Park J; Park H; Jang HW; Choe JH; Kim JH; Kim JS; Cho YS; Choi JY; Kim TH; Chung JH; Kim SW
Thyroid; 2021 Aug; 31(8):1264-1271. PubMed ID: 33947272
[No Abstract] [Full Text] [Related]
22. TSH receptor specific monoclonal autoantibody K1-70
Furmaniak J; Sanders J; Sanders P; Li Y; Rees Smith B
Clin Endocrinol (Oxf); 2022 Jun; 96(6):878-887. PubMed ID: 35088429
[TBL] [Abstract][Full Text] [Related]
23. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
24. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
[TBL] [Abstract][Full Text] [Related]
26. 2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease.
Parameswaran R; de Jong MC; Kit JLW; Sek K; Nam TQ; Thang TV; Khue NT; Aye TT; Tun PM; Cole T; Miller JA; Villa M; Khiewvan B; Sirinvaravong S; Sin YL; Muhammad R; Jap TS; Agrawal A; Rajput R; Fernando R; Sumanatilleke M; Suastika K; Shong YK; Lang B; Bartalena L; Yang SP;
Endocrine; 2023 Jan; 79(1):135-142. PubMed ID: 36129592
[TBL] [Abstract][Full Text] [Related]
27. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.
Träisk F; Tallstedt L; Abraham-Nordling M; Andersson T; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Ponjavic V; Taube A; Törring O; Wallin G; Asman P; Lundell G;
J Clin Endocrinol Metab; 2009 Oct; 94(10):3700-7. PubMed ID: 19723755
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.
Sundaresh V; Brito JP; Wang Z; Prokop LJ; Stan MN; Murad MH; Bahn RS
J Clin Endocrinol Metab; 2013 Sep; 98(9):3671-7. PubMed ID: 23824415
[TBL] [Abstract][Full Text] [Related]
29. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
30. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
31. Non-thionamide antithyroid drug options in Graves' hyperthyroidism.
Ruslan A; Okosieme OE
Expert Rev Endocrinol Metab; 2023 Jan; 18(1):67-79. PubMed ID: 36740774
[TBL] [Abstract][Full Text] [Related]
32. A comparison of cardiovascular disease, cancer, mortality, and Graves' ophthalmopathy following treatment for hyperthyroidism: A Bayesian network meta-analysis.
Liu X; Wong CKH; Wu T; Chan WWL; Woo YC; Lam CLK; Lang BHH
World J Surg; 2024 Feb; 48(2):393-407. PubMed ID: 38686801
[TBL] [Abstract][Full Text] [Related]
33. Outcome Prediction of Treatment of Graves' Hyperthyroidism with Antithyroid Drugs.
Piantanida E; Lai A; Sassi L; Gallo D; Spreafico E; Tanda ML; Bartalena L
Horm Metab Res; 2015 Sep; 47(10):767-72. PubMed ID: 26197855
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
Fung MHM; Lang BHH
Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
36. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
37. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
38. Thyrotoxicosis.
Franklyn JA; Boelaert K
Lancet; 2012 Mar; 379(9821):1155-66. PubMed ID: 22394559
[TBL] [Abstract][Full Text] [Related]
39. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy.
Elbers L; Mourits M; Wiersinga W
Thyroid; 2011 Mar; 21(3):279-83. PubMed ID: 21190446
[TBL] [Abstract][Full Text] [Related]
40. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study.
Brito JP; Payne S; Singh Ospina N; Rodriguez-Gutierrez R; Maraka S; Sangaralingham LR; Iñiguez-Ariza NM; Montori VM; Stan MN
Thyroid; 2020 Mar; 30(3):357-364. PubMed ID: 31973681
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]